首页 > 最新文献

Cardiovascular Drugs and Therapy最新文献

英文 中文
The Role of CTRP5 in Cardiovascular Disease: Friend or Foe? CTRP5 在心血管疾病中的作用:是敌是友?
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1007/s10557-024-07640-7
Yang Chen, Xiao-Juan Han, Hai-Ling Hu
{"title":"The Role of CTRP5 in Cardiovascular Disease: Friend or Foe?","authors":"Yang Chen, Xiao-Juan Han, Hai-Ling Hu","doi":"10.1007/s10557-024-07640-7","DOIUrl":"https://doi.org/10.1007/s10557-024-07640-7","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gab1 in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area. 心血管疾病中的 Gab1:一个尚未得到充分探索且存在争议的研究领域
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1007/s10557-024-07638-1
Da-Tan Jing, Fei Li, Li-Ying Ren
{"title":"Gab1 in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area.","authors":"Da-Tan Jing, Fei Li, Li-Ying Ren","doi":"10.1007/s10557-024-07638-1","DOIUrl":"https://doi.org/10.1007/s10557-024-07638-1","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Accolades for GLP-1 Research: Recognizing Pioneers in Diabetes and Obesity Treatment Across Five Prestigious Awards. GLP-1 研究获得国际殊荣:表彰糖尿病和肥胖症治疗领域的先驱,共获五项殊荣。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 DOI: 10.1007/s10557-024-07630-9
Tianru Jin, Y Eugene Chen
{"title":"International Accolades for GLP-1 Research: Recognizing Pioneers in Diabetes and Obesity Treatment Across Five Prestigious Awards.","authors":"Tianru Jin, Y Eugene Chen","doi":"10.1007/s10557-024-07630-9","DOIUrl":"https://doi.org/10.1007/s10557-024-07630-9","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Statin Treatment on Lipoprotein-Associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. 他汀类药物治疗对脂蛋白相关磷脂酶 A2 质量和活性的影响:随机安慰剂对照试验的系统回顾和元分析》。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-28 DOI: 10.1007/s10557-024-07634-5
Amirhossein Sahebkar, Željko Reiner, Wael Almahmeed, Tannaz Jamialahmadi, Luis E Simental-Mendía

Purpose: The goal of this meta-analysis was to establish whether statin treatment reduces Lp-PLA2 mass concentration and/or activity.

Methods: PubMed, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched using MESH terms and keywords. Randomized controlled trials (RCT) with either parallel or cross-over design examining the effect of statins on Lp-PLA2 mass and/or activity were included in meta-analysis.

Results: Out of 256 articles, 10 RCT were selected for meta-analysis. Statin therapy significantly reduced both Lp-PLA2 mass (WMD -44.46 ng/mL; 95%CI -59.01, -29.90; p < 0.001; I2 = 93%) and activity (WMD -39.37 nmol/min/mL; 95%CI -69.99, -8.75; p = 0.01; I2 = 100%). The sensitivity analysis was robust for Lp-PLA2 mass and was also positive for two studies concerning Lp-PLA2 activity.

Conclusion: Statin therapy significantly reduced both Lp-PLA2 mass and activity.

目的:本荟萃分析旨在确定他汀类药物治疗是否能降低脂蛋白-PLA2 的质量浓度和/或活性:使用 MESH 术语和关键词检索了 PubMed、Scopus、Web of Science、ClinicalTrials.gov 和 Google Scholar 数据库。荟萃分析纳入了采用平行或交叉设计、研究他汀类药物对 Lp-PLA2 质量和/或活性影响的随机对照试验(RCT):在256篇文章中,有10项RCT被选中进行荟萃分析。他汀类药物治疗可明显降低Lp-PLA2的质量(WMD -44.46 ng/mL;95%CI -59.01,-29.90;p < 0.001;I2 = 93%)和活性(WMD -39.37 nmol/min/mL;95%CI -69.99,-8.75;p = 0.01;I2 = 100%)。对脂蛋白磷酸化酶质量的敏感性分析是稳健的,对两项有关脂蛋白磷酸化酶活性的研究也是积极的:结论:他汀类药物治疗可明显降低脂蛋白-PLA2的质量和活性。
{"title":"Effect of Statin Treatment on Lipoprotein-Associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.","authors":"Amirhossein Sahebkar, Željko Reiner, Wael Almahmeed, Tannaz Jamialahmadi, Luis E Simental-Mendía","doi":"10.1007/s10557-024-07634-5","DOIUrl":"https://doi.org/10.1007/s10557-024-07634-5","url":null,"abstract":"<p><strong>Purpose: </strong>The goal of this meta-analysis was to establish whether statin treatment reduces Lp-PLA2 mass concentration and/or activity.</p><p><strong>Methods: </strong>PubMed, Scopus, Web of Science, ClinicalTrials.gov, and Google Scholar databases were searched using MESH terms and keywords. Randomized controlled trials (RCT) with either parallel or cross-over design examining the effect of statins on Lp-PLA2 mass and/or activity were included in meta-analysis.</p><p><strong>Results: </strong>Out of 256 articles, 10 RCT were selected for meta-analysis. Statin therapy significantly reduced both Lp-PLA2 mass (WMD -44.46 ng/mL; 95%CI -59.01, -29.90; p < 0.001; I<sup>2</sup> = 93%) and activity (WMD -39.37 nmol/min/mL; 95%CI -69.99, -8.75; p = 0.01; I<sup>2</sup> = 100%). The sensitivity analysis was robust for Lp-PLA2 mass and was also positive for two studies concerning Lp-PLA2 activity.</p><p><strong>Conclusion: </strong>Statin therapy significantly reduced both Lp-PLA2 mass and activity.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ticagrelor versus Clopidogrel in Patients with left main Coronary Artery Stenting. 左主干冠状动脉支架置入术患者服用替卡格雷与氯吡格雷的比较
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-26 DOI: 10.1007/s10557-024-07636-3
Yufeng Yan, Haimei Xu, Yingying Zhao, Song Lin, Yaguo Zheng

Purpose: The left main (LM) coronary artery disease poses high risks for its special anatomical characteristics. Optimal antiplatelet therapy is still controversial in this disease. We aimed to investigate the efficacy and safety of ticagrelor and clopidogrel in patients with stent implantation in the LM coronary artery.

Methods: We analyzed 3221 patients with stent implantation in the LM coronary artery from January 2011 to June 2022. Patients were separated into two groups: the ticagrelor group (n = 1550) and the clopidogrel group (n = 1671). Baseline data were balanced by propensity score matching. The primary endpoint was all-cause mortality, and secondary endpoints included cardiovascular death, myocardial infarction, stroke, stent thrombosis, or target vessel revascularization. The primary safety endpoint was major bleeding, defined as BARC 3, 5 bleeding.

Results: After propensity score matching (n = 1228 in each group), ticagrelor was linked to a lower incidence of all-cause mortality compared with clopidogrel after a three-year follow-up (5.7% vs. 8.5%; HR:0.728; 95%CI:0.537-0.985, P = 0.040). Ticagrelor treatment reduced target lesion revascularization (3.3% vs. 6.4%; HR: 0.542; 95%CI: 0.371-0.791, P = 0.001) and stent thrombosis (1.6% vs. 3.7%; HR: 0.459; 95%CI: 0.271-0.776, P = 0.004). There was no significant difference in major bleeding between the two groups. Multivariate COX analysis suggested that age, heart rate, diabetes, prior myocardial infarction, hemoglobin, serum creatinine, ticagrelor, DAPT duration, LM true-bifurcation, LM stent diameters, and IVUS were independent predictive parameters of all-cause death.

Conclusions: Ticagrelor was associated with lower all-cause mortality and no increased risk of major bleeding compared to clopidogrel in LM stenting patients. Thus, ticagrelor can be considered a viable substitute for clopidogrel in LM disease.

目的:左主干(LM)冠状动脉疾病因其特殊的解剖特征而具有高风险。对于这种疾病,最佳抗血小板疗法仍存在争议。我们旨在研究在左主干冠状动脉植入支架的患者中使用替卡格雷和氯吡格雷的有效性和安全性:我们分析了2011年1月至2022年6月期间3221名在左冠状动脉植入支架的患者。患者分为两组:替卡格雷组(n = 1550)和氯吡格雷组(n = 1671)。基线数据通过倾向评分匹配进行平衡。主要终点是全因死亡率,次要终点包括心血管死亡、心肌梗死、中风、支架血栓或靶血管血运重建。主要安全性终点是大出血,定义为 BARC 3、5 级出血:倾向评分匹配后(每组1228人),随访三年后,与氯吡格雷相比,替卡格雷的全因死亡率更低(5.7% vs. 8.5%;HR:0.728;95%CI:0.537-0.985,P = 0.040)。替卡格雷治疗减少了靶病变血运重建(3.3% 对 6.4%;HR:0.542;95%CI:0.371-0.791,P = 0.001)和支架血栓形成(1.6% 对 3.7%;HR:0.459;95%CI:0.271-0.776,P = 0.004)。两组在大出血方面没有明显差异。多变量COX分析表明,年龄、心率、糖尿病、既往心肌梗死、血红蛋白、血清肌酐、替卡格雷、DAPT持续时间、LM真分叉、LM支架直径和IVUS是全因死亡的独立预测参数:与氯吡格雷相比,替卡格雷可降低LM支架置入患者的全因死亡率,且不会增加大出血风险。因此,在LM疾病中,替卡格雷可被视为氯吡格雷的可行替代品。
{"title":"Ticagrelor versus Clopidogrel in Patients with left main Coronary Artery Stenting.","authors":"Yufeng Yan, Haimei Xu, Yingying Zhao, Song Lin, Yaguo Zheng","doi":"10.1007/s10557-024-07636-3","DOIUrl":"https://doi.org/10.1007/s10557-024-07636-3","url":null,"abstract":"<p><strong>Purpose: </strong>The left main (LM) coronary artery disease poses high risks for its special anatomical characteristics. Optimal antiplatelet therapy is still controversial in this disease. We aimed to investigate the efficacy and safety of ticagrelor and clopidogrel in patients with stent implantation in the LM coronary artery.</p><p><strong>Methods: </strong>We analyzed 3221 patients with stent implantation in the LM coronary artery from January 2011 to June 2022. Patients were separated into two groups: the ticagrelor group (n = 1550) and the clopidogrel group (n = 1671). Baseline data were balanced by propensity score matching. The primary endpoint was all-cause mortality, and secondary endpoints included cardiovascular death, myocardial infarction, stroke, stent thrombosis, or target vessel revascularization. The primary safety endpoint was major bleeding, defined as BARC 3, 5 bleeding.</p><p><strong>Results: </strong>After propensity score matching (n = 1228 in each group), ticagrelor was linked to a lower incidence of all-cause mortality compared with clopidogrel after a three-year follow-up (5.7% vs. 8.5%; HR:0.728; 95%CI:0.537-0.985, P = 0.040). Ticagrelor treatment reduced target lesion revascularization (3.3% vs. 6.4%; HR: 0.542; 95%CI: 0.371-0.791, P = 0.001) and stent thrombosis (1.6% vs. 3.7%; HR: 0.459; 95%CI: 0.271-0.776, P = 0.004). There was no significant difference in major bleeding between the two groups. Multivariate COX analysis suggested that age, heart rate, diabetes, prior myocardial infarction, hemoglobin, serum creatinine, ticagrelor, DAPT duration, LM true-bifurcation, LM stent diameters, and IVUS were independent predictive parameters of all-cause death.</p><p><strong>Conclusions: </strong>Ticagrelor was associated with lower all-cause mortality and no increased risk of major bleeding compared to clopidogrel in LM stenting patients. Thus, ticagrelor can be considered a viable substitute for clopidogrel in LM disease.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. 新型抗凝剂治疗癌症患者静脉血栓栓塞症的临床疗效和安全性:系统回顾与元分析》。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-21 DOI: 10.1007/s10557-024-07620-x
Mei-Chuan Lee, Jheng-Yan Wu, Tsung Yu, Chia-Te Liao, Wei-Ting Chang, Han Siong Toh, Kuo-Chuan Hung, Hui-Chen Su

Purpose: Cancer patients face a four- to sevenfold higher risk of venous thromboembolism (VTE) than the general population. Novel oral anticoagulants (NOACs) provide convenient alternatives to traditional therapies.

Methods: We performed a systematic literature search across PubMed, Embase, and the Cochrane Library, targeting studies that examined the use of NOACs in cancer-associated VTE. The search included randomized controlled trials (RCTs). Selected studies compared NOACs with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKA) in cancer patients diagnosed with VTE. A meta-analysis using a random-effects model was applied to estimate pooled effect sizes for outcomes.

Results: In this meta-analysis, we included 12 RCTs. Results showed NOACs were more effective than LMWH in preventing VTE recurrence (RR 0.66, 95% CI 0.52-0.83, p = 0.0004). Compared with VKAs, NOACs showed no significant difference (RR 0.63, 95% CI 0.34-1.15, p = 0.13). However, this finding is limited by the small patient sample. Major bleeding outcomes were similar between NOACs and LMWH/VKAs (RR 1.24, 95% CI 0.85-1.80, p = 0.28; RR 0.77, 95% CI 0.39-1.53, p = 0.46, respectively). Meta-regression analysis indicated a statistically significant positive correlation between mortality and major bleeding events when comparing NOACs with LMWH (p = 0.049). There was no significant difference in all-cause mortality between patients treated with NOACs and those treated with LMWH (RR 1.04, 95% CI 0.92-1.18, p = 0.54) or VKAs (RR 0.94, 95% CI 0.72-1.23, p = 0.65).

Conclusion: Meta-analysis shows NOACs, especially factor Xa inhibitors, reduce VTE recurrence in cancer patients more effectively than LMWH. Comparison between NOACs and VKAs is inconclusive due to limited patient data. Further research is needed to assess NOACs' efficacy and safety against VKAs.

目的:癌症患者罹患静脉血栓栓塞症(VTE)的风险是普通人群的四到七倍。新型口服抗凝药(NOAC)为传统疗法提供了便捷的替代品:我们在 PubMed、Embase 和 Cochrane 图书馆进行了系统性文献检索,目标是研究 NOACs 在癌症相关 VTE 中的应用。检索包括随机对照试验(RCT)。所选研究将 NOAC 与低分子量肝素 (LMWH) 或维生素 K 拮抗剂 (VKA) 用于确诊为 VTE 的癌症患者进行了比较。采用随机效应模型进行荟萃分析,以估计结果的集合效应大小:在这项荟萃分析中,我们纳入了 12 项研究。结果显示,在预防 VTE 复发方面,NOAC 比 LMWH 更有效(RR 0.66,95% CI 0.52-0.83,P = 0.0004)。与 VKAs 相比,NOACs 没有明显差异(RR 0.63,95% CI 0.34-1.15,p = 0.13)。然而,由于患者样本较少,这一结果受到了限制。NOAC与LMWH/VKAs的大出血结果相似(RR分别为1.24,95% CI为0.85-1.80,p = 0.28;RR分别为0.77,95% CI为0.39-1.53,p = 0.46)。元回归分析表明,NOAC 与 LMWH 相比,死亡率与大出血事件之间存在统计学意义上的显著正相关性(p = 0.049)。NOACs与LMWH(RR 1.04,95% CI 0.92-1.18,p = 0.54)或VKAs(RR 0.94,95% CI 0.72-1.23,p = 0.65)治疗患者的全因死亡率无明显差异:Meta分析表明,NOACs(尤其是Xa因子抑制剂)比LMWH能更有效地减少癌症患者的VTE复发。由于患者数据有限,NOAC 与 VKAs 之间的比较尚无定论。需要进一步研究来评估 NOAC 与 VKAs 的疗效和安全性。
{"title":"Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis.","authors":"Mei-Chuan Lee, Jheng-Yan Wu, Tsung Yu, Chia-Te Liao, Wei-Ting Chang, Han Siong Toh, Kuo-Chuan Hung, Hui-Chen Su","doi":"10.1007/s10557-024-07620-x","DOIUrl":"https://doi.org/10.1007/s10557-024-07620-x","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer patients face a four- to sevenfold higher risk of venous thromboembolism (VTE) than the general population. Novel oral anticoagulants (NOACs) provide convenient alternatives to traditional therapies.</p><p><strong>Methods: </strong>We performed a systematic literature search across PubMed, Embase, and the Cochrane Library, targeting studies that examined the use of NOACs in cancer-associated VTE. The search included randomized controlled trials (RCTs). Selected studies compared NOACs with low-molecular-weight heparin (LMWH) or vitamin K antagonists (VKA) in cancer patients diagnosed with VTE. A meta-analysis using a random-effects model was applied to estimate pooled effect sizes for outcomes.</p><p><strong>Results: </strong>In this meta-analysis, we included 12 RCTs. Results showed NOACs were more effective than LMWH in preventing VTE recurrence (RR 0.66, 95% CI 0.52-0.83, p = 0.0004). Compared with VKAs, NOACs showed no significant difference (RR 0.63, 95% CI 0.34-1.15, p = 0.13). However, this finding is limited by the small patient sample. Major bleeding outcomes were similar between NOACs and LMWH/VKAs (RR 1.24, 95% CI 0.85-1.80, p = 0.28; RR 0.77, 95% CI 0.39-1.53, p = 0.46, respectively). Meta-regression analysis indicated a statistically significant positive correlation between mortality and major bleeding events when comparing NOACs with LMWH (p = 0.049). There was no significant difference in all-cause mortality between patients treated with NOACs and those treated with LMWH (RR 1.04, 95% CI 0.92-1.18, p = 0.54) or VKAs (RR 0.94, 95% CI 0.72-1.23, p = 0.65).</p><p><strong>Conclusion: </strong>Meta-analysis shows NOACs, especially factor Xa inhibitors, reduce VTE recurrence in cancer patients more effectively than LMWH. Comparison between NOACs and VKAs is inconclusive due to limited patient data. Further research is needed to assess NOACs' efficacy and safety against VKAs.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Inhibition of Drp1 Mitigates Adverse Cardiac Remodelling following Chronic Reperfused Myocardial Infarction. 急性抑制 Drp1 可减轻慢性再灌注心肌梗死后的不良心脏重构。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-21 DOI: 10.1007/s10557-024-07633-6
Daniel G Donner, Anne M Kong, Jarmon G Lees, Helen Kiriazis, Aascha Brown, Yow K Tham, Jessica K Holien, Hsin-Hui Shen, Derek J Hausenloy, Shiang Y Lim
{"title":"Acute Inhibition of Drp1 Mitigates Adverse Cardiac Remodelling following Chronic Reperfused Myocardial Infarction.","authors":"Daniel G Donner, Anne M Kong, Jarmon G Lees, Helen Kiriazis, Aascha Brown, Yow K Tham, Jessica K Holien, Hsin-Hui Shen, Derek J Hausenloy, Shiang Y Lim","doi":"10.1007/s10557-024-07633-6","DOIUrl":"https://doi.org/10.1007/s10557-024-07633-6","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142458680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study. 低剂量普拉格雷对经皮冠状动脉介入术后慢性期血小板反应性的影响(CHAPERON):一项前瞻性队列研究。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2023-04-25 DOI: 10.1007/s10557-023-07454-z
Tatsuya Fukase, Shinichiro Doi, Tomotaka Dohi, Takuma Koike, Ryota Nishio, Hidetoshi Yasuda, Mitsuhiro Takeuchi, Norihito Takahashi, Yuichi Chikata, Hirohisa Endo, Hiroki Nishiyama, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Hiroyuki Daida, Satoru Suwa, Tohru Minamino, Katsumi Miyauchi

Purpose: Asians often face the problems of clopidogrel resistance and East Asian paradox. This study aimed to evaluate the effects of P2Y12 inhibitors, including low-dose prasugrel 2.5 mg, on the P2Y12 reaction unit (PRU) in the chronic phase after percutaneous coronary intervention (PCI).

Methods: A total of 348 patients were studied. PRU was measured 6-12 months after PCI and subsequently, 6 months later using a P2Y12 assay, respectively. This study evaluated the proportion of bleeding risk (PRU ≤ 85) and ischemic risk (PRU ≥ 239) as primary endpoints, and the prediction of bleeding risk and ischemic risk using multivariable logistic regression analysis.

Results: At baseline, 136 patients (39%) received prasugrel 3.75 mg, 48 patients (14%) received prasugrel 2.5 mg, and 164 patients (47%) received clopidogrel 75 mg. Clopidogrel 75 mg had a significantly higher proportion of ischemic risk within one year after PCI than the other groups, and was an independent predictor for ischemic risk with reference of prasugrel 3.75 mg. In addition, switching from clopidogrel 75 mg to prasugrel 2.5 mg significantly lowered and aggregated the PRU value. Whereas, dose reduction of prasugrel had a significantly lower proportion of bleeding risk over one year after PCI than the continuation of prasugrel 3.75 mg, and was an independent predictor for bleeding risk with reference of continuation of prasugrel 3.75 mg.

Conclusions: Prasugrel 2.5 mg has a lower ischemic risk and a more stable PRU value compared with clopidogrel treatment. Prasugrel also contributes to a decline in bleeding risk with concomitant dose reduction.

Trial registration: University Hospital Medical Information Network (UMIN), ID: UMIN000029541, Date: October 16, 2017 ( https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033395 ).

目的:亚洲人经常面临氯吡格雷耐药和东亚悖论的问题。本研究旨在评估 P2Y12 抑制剂(包括小剂量普拉格雷 2.5 毫克)对经皮冠状动脉介入治疗(PCI)后慢性期 P2Y12 反应单位(PRU)的影响:共研究了 348 例患者。分别在 PCI 术后 6-12 个月和 6 个月后使用 P2Y12 检测法测量 PRU。该研究以出血风险(PRU ≤ 85)和缺血风险(PRU ≥ 239)的比例作为主要终点,并使用多变量逻辑回归分析预测出血风险和缺血风险:基线时,136 名患者(39%)接受普拉格雷 3.75 毫克治疗,48 名患者(14%)接受普拉格雷 2.5 毫克治疗,164 名患者(47%)接受氯吡格雷 75 毫克治疗。与其他组相比,氯吡格雷 75 毫克患者在 PCI 术后一年内的缺血风险比例明显更高,并且是普拉格雷 3.75 毫克患者缺血风险的独立预测因素。此外,将氯吡格雷 75 毫克换成普拉格雷 2.5 毫克可显著降低和聚集 PRU 值。而减少普拉格雷的剂量在PCI术后一年内的出血风险比例明显低于继续使用普拉格雷3.75毫克,并且是继续使用普拉格雷3.75毫克的出血风险的独立预测因素:结论:与氯吡格雷治疗相比,普拉格雷2.5 mg的缺血风险更低,PRU值更稳定。普拉格雷还有助于在减少剂量的同时降低出血风险:试验注册:大学医院医学信息网(UMIN),ID:UMIN000029541, Date:2017年10月16日( https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033395 )。
{"title":"Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study.","authors":"Tatsuya Fukase, Shinichiro Doi, Tomotaka Dohi, Takuma Koike, Ryota Nishio, Hidetoshi Yasuda, Mitsuhiro Takeuchi, Norihito Takahashi, Yuichi Chikata, Hirohisa Endo, Hiroki Nishiyama, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Hiroyuki Daida, Satoru Suwa, Tohru Minamino, Katsumi Miyauchi","doi":"10.1007/s10557-023-07454-z","DOIUrl":"10.1007/s10557-023-07454-z","url":null,"abstract":"<p><strong>Purpose: </strong>Asians often face the problems of clopidogrel resistance and East Asian paradox. This study aimed to evaluate the effects of P2Y<sub>12</sub> inhibitors, including low-dose prasugrel 2.5 mg, on the P2Y<sub>12</sub> reaction unit (PRU) in the chronic phase after percutaneous coronary intervention (PCI).</p><p><strong>Methods: </strong>A total of 348 patients were studied. PRU was measured 6-12 months after PCI and subsequently, 6 months later using a P2Y<sub>12</sub> assay, respectively. This study evaluated the proportion of bleeding risk (PRU ≤ 85) and ischemic risk (PRU ≥ 239) as primary endpoints, and the prediction of bleeding risk and ischemic risk using multivariable logistic regression analysis.</p><p><strong>Results: </strong>At baseline, 136 patients (39%) received prasugrel 3.75 mg, 48 patients (14%) received prasugrel 2.5 mg, and 164 patients (47%) received clopidogrel 75 mg. Clopidogrel 75 mg had a significantly higher proportion of ischemic risk within one year after PCI than the other groups, and was an independent predictor for ischemic risk with reference of prasugrel 3.75 mg. In addition, switching from clopidogrel 75 mg to prasugrel 2.5 mg significantly lowered and aggregated the PRU value. Whereas, dose reduction of prasugrel had a significantly lower proportion of bleeding risk over one year after PCI than the continuation of prasugrel 3.75 mg, and was an independent predictor for bleeding risk with reference of continuation of prasugrel 3.75 mg.</p><p><strong>Conclusions: </strong>Prasugrel 2.5 mg has a lower ischemic risk and a more stable PRU value compared with clopidogrel treatment. Prasugrel also contributes to a decline in bleeding risk with concomitant dose reduction.</p><p><strong>Trial registration: </strong>University Hospital Medical Information Network (UMIN), ID: UMIN000029541, Date: October 16, 2017 ( https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033395 ).</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"947-957"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential. 病理性心肌肥大中的调节性 T 细胞:机制与治疗潜力》。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2023-05-15 DOI: 10.1007/s10557-023-07463-y
Leiling Liu, Jiahui Hu, Hao Lei, Huali Qin, Chunfang Wang, Yajun Gui, Danyan Xu

Background: Pathological cardiac hypertrophy is linked to immune-inflammatory injury, and regulatory T cells (Tregs) play a crucial role in suppressing immune-inflammatory responses. However, the precise role of Tregs in pathological cardiac hypertrophy remains unclear.

Objective: To summarize the current knowledge on the role and mechanisms of Tregs in pathological cardiac hypertrophy and explore their perspectives and challenges as a new therapeutic approach.

Results: Treg cells may play an important protective role in pressure overload (hypertension, aortic stenosis), myocardial infarction, metabolic disorders (diabetes, obesity), acute myocarditis, cardiomyopathy (hypertrophic cardiomyopathy, storage diseases), and chronic obstructive pulmonary disease-related pathological cardiac hypertrophy. Although some challenges remain, the safety and efficacy of Treg-based therapies have been confirmed in some clinical trials, and engineered antigen-specific Treg cells may have better clinical application prospects due to stronger immunosuppressive function and stability.

Conclusion: Targeting the immune-inflammatory response via Treg-based therapies might provide a promising and novel future approach to the prevention and treatment of pathological cardiac hypertrophy.

背景:病理性心肌肥厚与免疫炎症损伤有关,而调节性 T 细胞(Tregs)在抑制免疫炎症反应中发挥着至关重要的作用。然而,Tregs在病理性心脏肥大中的确切作用仍不清楚:总结Tregs在病理性心肌肥厚中的作用和机制的现有知识,并探讨其作为一种新的治疗方法的前景和挑战:结果:Treg细胞在压力超负荷(高血压、主动脉瓣狭窄)、心肌梗死、代谢紊乱(糖尿病、肥胖)、急性心肌炎、心肌病(肥厚型心肌病、储能性疾病)和慢性阻塞性肺疾病相关的病理性心脏肥大中可能发挥重要的保护作用。尽管仍存在一些挑战,但基于Treg的疗法的安全性和有效性已在一些临床试验中得到证实,而工程化的抗原特异性Treg细胞由于具有更强的免疫抑制功能和稳定性,可能具有更好的临床应用前景:结论:通过基于 Treg 的疗法靶向免疫炎症反应可能为预防和治疗病理性心肌肥厚提供一种前景广阔的新方法。
{"title":"Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential.","authors":"Leiling Liu, Jiahui Hu, Hao Lei, Huali Qin, Chunfang Wang, Yajun Gui, Danyan Xu","doi":"10.1007/s10557-023-07463-y","DOIUrl":"10.1007/s10557-023-07463-y","url":null,"abstract":"<p><strong>Background: </strong>Pathological cardiac hypertrophy is linked to immune-inflammatory injury, and regulatory T cells (Tregs) play a crucial role in suppressing immune-inflammatory responses. However, the precise role of Tregs in pathological cardiac hypertrophy remains unclear.</p><p><strong>Objective: </strong>To summarize the current knowledge on the role and mechanisms of Tregs in pathological cardiac hypertrophy and explore their perspectives and challenges as a new therapeutic approach.</p><p><strong>Results: </strong>Treg cells may play an important protective role in pressure overload (hypertension, aortic stenosis), myocardial infarction, metabolic disorders (diabetes, obesity), acute myocarditis, cardiomyopathy (hypertrophic cardiomyopathy, storage diseases), and chronic obstructive pulmonary disease-related pathological cardiac hypertrophy. Although some challenges remain, the safety and efficacy of Treg-based therapies have been confirmed in some clinical trials, and engineered antigen-specific Treg cells may have better clinical application prospects due to stronger immunosuppressive function and stability.</p><p><strong>Conclusion: </strong>Targeting the immune-inflammatory response via Treg-based therapies might provide a promising and novel future approach to the prevention and treatment of pathological cardiac hypertrophy.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"999-1015"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9462020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex Interplay Between Metabolism and CD4+ T-Cell Activation, Differentiation, and Function: a Novel Perspective for Atherosclerosis Immunotherapy. 新陈代谢与 CD4+ T 细胞活化、分化和功能之间的复杂相互作用:动脉粥样硬化免疫疗法的新视角。
IF 3.1 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 Epub Date: 2023-05-18 DOI: 10.1007/s10557-023-07466-9
Jingmin Yang, Yanying Chen, Xiao Li, Huali Qin, Jinghui Bao, Chunfang Wang, Xiaochen Dong, Danyan Xu

Atherosclerosis is a complex pathological process that results from the chronic inflammatory reaction of the blood vessel wall and involves various immune cells and cytokines. An imbalance in the proportion and function of the effector CD4+ T-cell (Teff) and regulatory T-cell (Treg) subsets is an important cause of the occurrence and development of atherosclerotic plaques. Teff cells depend on glycolytic metabolism and glutamine catabolic metabolism for energy, while Treg cells mainly rely on fatty acid oxidation (FAO), which is crucial for determining the fate of CD4+ T cells during differentiation and maintaining their respective immune functions. Here, we review recent research achievements in the field of immunometabolism related to CD4+ T cells, focusing on the cellular metabolic pathways and metabolic reprogramming involved in the activation, proliferation, and differentiation of CD4+ T cells. Subsequently, we discuss the important roles of mTOR and AMPK signaling in regulating CD4+ T-cell differentiation. Finally, we evaluated the links between CD4+ T-cell metabolism and atherosclerosis, highlighting the potential of targeted modulation of CD4+ T-cell metabolism in the prevention and treatment of atherosclerosis in the future.

动脉粥样硬化是一种复杂的病理过程,是血管壁慢性炎症反应的结果,涉及各种免疫细胞和细胞因子。效应 CD4+ T 细胞(Teff)和调节性 T 细胞(Treg)亚群的比例和功能失衡是动脉粥样硬化斑块发生和发展的重要原因。Teff细胞依赖糖酵解代谢和谷氨酰胺分解代谢获得能量,而Treg细胞主要依赖脂肪酸氧化(FAO),这对CD4+ T细胞在分化过程中决定命运和维持各自的免疫功能至关重要。在此,我们回顾了与 CD4+ T 细胞相关的免疫代谢领域的最新研究成果,重点关注 CD4+ T 细胞活化、增殖和分化过程中涉及的细胞代谢途径和代谢重编程。随后,我们讨论了 mTOR 和 AMPK 信号在调控 CD4+ T 细胞分化中的重要作用。最后,我们评估了 CD4+ T 细胞代谢与动脉粥样硬化之间的联系,强调了靶向调节 CD4+ T 细胞代谢在未来预防和治疗动脉粥样硬化中的潜力。
{"title":"Complex Interplay Between Metabolism and CD4<sup>+</sup> T-Cell Activation, Differentiation, and Function: a Novel Perspective for Atherosclerosis Immunotherapy.","authors":"Jingmin Yang, Yanying Chen, Xiao Li, Huali Qin, Jinghui Bao, Chunfang Wang, Xiaochen Dong, Danyan Xu","doi":"10.1007/s10557-023-07466-9","DOIUrl":"10.1007/s10557-023-07466-9","url":null,"abstract":"<p><p>Atherosclerosis is a complex pathological process that results from the chronic inflammatory reaction of the blood vessel wall and involves various immune cells and cytokines. An imbalance in the proportion and function of the effector CD4<sup>+</sup> T-cell (Teff) and regulatory T-cell (Treg) subsets is an important cause of the occurrence and development of atherosclerotic plaques. Teff cells depend on glycolytic metabolism and glutamine catabolic metabolism for energy, while Treg cells mainly rely on fatty acid oxidation (FAO), which is crucial for determining the fate of CD4<sup>+</sup> T cells during differentiation and maintaining their respective immune functions. Here, we review recent research achievements in the field of immunometabolism related to CD4<sup>+</sup> T cells, focusing on the cellular metabolic pathways and metabolic reprogramming involved in the activation, proliferation, and differentiation of CD4<sup>+</sup> T cells. Subsequently, we discuss the important roles of mTOR and AMPK signaling in regulating CD4<sup>+</sup> T-cell differentiation. Finally, we evaluated the links between CD4<sup>+</sup> T-cell metabolism and atherosclerosis, highlighting the potential of targeted modulation of CD4<sup>+</sup> T-cell metabolism in the prevention and treatment of atherosclerosis in the future.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"1033-1046"},"PeriodicalIF":3.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9473321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular Drugs and Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1